Table 2.
Current rheumatoid arthritis medications.
| Medication | Study population, n (%) | ||
| Group A (n=194) | Group B (n=194) | Total (n=388) | |
| Painkillers | 89 (45.9) | 81 (41.8) | 170 (43.8) |
| NSAIDsa | 111 (57.2) | 83 (42.8) | 194 (50.0) |
| Corticosteroids | 57 (29.4) | 60 (30.9) | 117 (30.2) |
| Methotrexate | 76 (39.2) | 79 (40.7) | 155 (39.9) |
| Azathioprine | 3 (1.5) | 2 (1.0) | 5 (1.3) |
| Auranofin | 1 (0.5) | 0 | 1 (0.3) |
| Chloroquine | 1 (0.5) | 0 | 1 (0.3) |
| Hydroxychloroquine | 46 (23.7) | 61 (31.4) | 107 (27.6) |
| Leflunomide | 13 (6.7) | 17 (8.8) | 30 (7.7) |
| Mycophenolate | 3 (1.5) | 0 | 3 (0.8) |
| Sulfasalazine | 11 (5.7) | 18 (9.3) | 29 (7.5) |
| Abatacept | 14 (7.2) | 15 (7.7) | 29 (7.5) |
| Adalimumab | 23 (11.9) | 19 (19.8) | 42 (10.8) |
| Certolizumab | 7 (3.6) | 3 (1.5) | 10 (2.6) |
| Etanercept | 14 (7.2) | 20 (10.3) | 34 (8.8) |
| Golimumab | 4 (2.1) | 7 (3.6) | 11 (2.8) |
| Infliximab | 6 (3.1) | 10 (5.2) | 16 (4.1) |
| Rituximab | 4 (2.1) | 7 (3.6) | 11 (2.8) |
| Tocilizumab | 7 (3.6) | 6 (3.1) | 13 (3.4) |
| Tofacitinib | 9 (4.6) | 9 (4.6) | 18 (4.6) |
| Others | 19 (9.8) | 21 (10.8) | 40 (10.3) |
aNSAID: nonsteroidal anti-inflammatory drug.